Variability in the Definition and Reporting of Adverse Events in Suicide Prevention Trials: An Examination of the Issues and a Proposed Solution

被引:6
作者
Oquendo, Maria A. [1 ]
Feldman, Sarah [1 ]
Silverman, Emily [1 ]
Currier, Dianne [2 ]
Brown, Gregory K. [3 ]
Chen, Donna [4 ]
Chiapella, Page [5 ]
Fischbach, Ruth [1 ]
Gould, Madelyn [1 ]
Stanley, Barbara [1 ]
Strauss, David [1 ]
Zelazny, Jamie [6 ]
Pearson, Jane [7 ]
机构
[1] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[2] Columbia Univ, Dept Psychiat, New York, NY USA
[3] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[4] Univ Virginia, Ctr Biomed Eth & Humanities, Charlottesville, VA USA
[5] NIAAA, Bethesda, MD USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] NIMH, Bethesda, MD 20892 USA
关键词
Adverse Events; safety; Serious Adverse Events; study evaluation; suicide research; TOWER-OF-BABEL; CLINICAL-TRIALS; SAFETY; INTERVENTION; NOMENCLATURE; MULTICENTER; IMPROVEMENT; BEHAVIOR; LESSONS; CARE;
D O I
10.1080/13811118.2011.541146
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Adverse events (AEs) and serious adverse events (SAEs) are important outcomes of any intervention study yet are under-researched. Vague and variable definitions and substantial underreporting make comparisons of risk between studies difficult and evaluation of the safety of a particular intervention almost impossible. These realities may deter researchers from studying at-risk populations. Suicidal behavior is an adverse event in any study, and potentially a very serious one. Thus the issues of reporting and definition are particularly salient for researchers who work with populations at risk for suicidal behavior, especially when the suicidal behavior is the outcome of interest. We conducted a qualitative study with experienced suicide researchers and intervention experts to delineate the issues related to reporting serious adverse events faced by investigators conducting trials in suicide prevention. Participants from multiple sites were interviewed by phone, interviews transcribed and coded for definition and reporting issues and suggested solutions. A narrative synthesis was prepared and validated by all participants. Participants highlighted the difficulties in defining AEs and SAEs and stressed the importance and complexity of ensuring the AE was related to the study and reported properly, and were in agreement about the consequences of AEs to both institutions and individuals. Participants identified the need for the development of clear and consistent AE definitions and reporting requirements. Clear and consistently applied definitions of adverse and serious adverse events and reporting requirements would enhance the comparability of intervention studies in suicidal populations.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 50 条
  • [11] Reporting of Serious Adverse Events During Cancer Clinical Trials to the Institutional Review Board: An Evaluation by the Research on Adverse Drug Events And Reports (RADAR) Project
    Belknap, S. M.
    Georgopoulos, C. H.
    Lagman, J.
    Weitzman, S. A.
    Qualkenbush, L.
    Yarnold, P. R.
    Edwards, B. J.
    McKoy, J. M.
    Trifilio, S. M.
    West, D. P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (12) : 1334 - 1340
  • [12] Serious adverse events reporting in clinical trials: Is it possible to reduce the background noise?
    Dheyriat, L.
    L'huillier, M.
    Bodenan, E.
    Blanc, E.
    Nguon, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 151 - 152
  • [13] Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting
    Gwenllian Moody
    Katy Addison
    Rebecca Cannings-John
    Julia Sanders
    Carolyn Wallace
    Michael Robling
    Trials, 20
  • [14] Analysis and reporting of adverse events in randomised controlled trials: a review
    Phillips, Rachel
    Hazell, Lorna
    Sauzet, Odile
    Cornelius, Victoria
    BMJ OPEN, 2019, 9 (02):
  • [15] Completeness of reporting of adverse events in trials of maintenance immunosuppression in kidney transplantation: a systematic review
    Howell, Martin
    Yeo, Reichelle
    Tong, Allison
    Craig, Jonathan C.
    Howard, Kirsten
    Wong, Germaine
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (09) : 1586 - +
  • [16] Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs
    Belknap, S. M.
    Georgopoulos, C. H.
    West, D. P.
    Yarnold, P. R.
    Kelly, W. N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 231 - 236
  • [17] Frequency of reporting of adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy
    Vaughan, Barney
    Goldstein, Michael H.
    Alikakos, Maria
    Cohen, Lisa J.
    Serby, Michael J.
    COMPREHENSIVE PSYCHIATRY, 2014, 55 (04) : 849 - 855
  • [18] Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies
    Mansi, Ishak
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2015, 350 (04) : 330 - 337
  • [19] Reporting of Adverse Events in Surgical Trials: Critical Appraisal of Current Practice
    Rosenthal, Rachel
    Hoffmann, Henry
    Dwan, Kerry
    Clavien, Pierre-Alain
    Bucher, Heiner C.
    WORLD JOURNAL OF SURGERY, 2015, 39 (01) : 80 - 87
  • [20] The reporting of adverse events associated with spinal manipulation in randomized clinical trials: an updated systematic review
    Gorrell, Lindsay M.
    Brown, Benjamin T.
    Engel, Roger
    Lystad, Reidar P.
    BMJ OPEN, 2024, 14 (01):